102 related articles for article (PubMed ID: 3286168)
1. Alpha-glucosidase inhibition and timing of preprandial insulin in patients with insulin-dependent diabetes mellitus (IDDM).
Kennedy FP; Gerich JE
Diabetes Res Clin Pract; 1988 Apr; 4(4):309-12. PubMed ID: 3286168
[TBL] [Abstract][Full Text] [Related]
2. A new alpha-glucosidase inhibitor (Bay-m-1099) reduces insulin requirements with meals in insulin-dependent diabetes mellitus.
Kennedy FP; Gerich JE
Clin Pharmacol Ther; 1987 Oct; 42(4):455-8. PubMed ID: 3311550
[TBL] [Abstract][Full Text] [Related]
3. Effects of alpha-glucosidase inhibition on meal glucose tolerance and timing of insulin administration in patients with type I diabetes mellitus.
Dimitriadis G; Hatziagellaki E; Alexopoulos E; Kordonouri O; Komesidou V; Ganotakis M; Raptis S
Diabetes Care; 1991 May; 14(5):393-8. PubMed ID: 2060451
[TBL] [Abstract][Full Text] [Related]
4. Alpha-glucosidase inhibition as an adjunct to the treatment of type 1 diabetes.
Tattersall R
Diabet Med; 1993 Oct; 10(8):688-93. PubMed ID: 8261749
[No Abstract] [Full Text] [Related]
5. Effect of alpha-glucosidase inhibition on glucose profiles in insulin dependent diabetes.
Hillman RJ; Scott M; Gray RS
Diabetes Res; 1989 Feb; 10(2):81-4. PubMed ID: 2663321
[TBL] [Abstract][Full Text] [Related]
6. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
Johnson AB; Taylor R
Diabetes Care; 1996 Jun; 19(6):559-63. PubMed ID: 8725851
[TBL] [Abstract][Full Text] [Related]
7. Effects of two new alpha-glucosidase inhibitors on glycemic control in patients with insulin-dependent diabetes mellitus.
Dimitriadis G; Raptis S; Raptis A; Hatziagelaki E; Mitrakou A; Halvatsiotis P; Ladas S; Hillebrand I
Klin Wochenschr; 1986 May; 64(9):405-10. PubMed ID: 3520133
[TBL] [Abstract][Full Text] [Related]
8. Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.
Heinz G; Komjati M; Korn A; Waldhäusl W
Eur J Clin Pharmacol; 1989; 37(1):33-6. PubMed ID: 2687007
[TBL] [Abstract][Full Text] [Related]
9. Effect of two new alpha-glucosidase inhibitors in insulin-dependent diabetic patients.
Serrano-Rios M; Sabán J; Navascués I; Cañizo JF; Hillebrand I
Diabetes Res Clin Pract; 1988 Jan; 4(2):111-6. PubMed ID: 3277827
[TBL] [Abstract][Full Text] [Related]
10. The effect of two new alpha-glucosidase inhibitors on metabolic responses to a mixed meal in normal volunteers.
Kennedy FP; Miles JM; Heiling V; Gerich JE
Clin Exp Pharmacol Physiol; 1987 Aug; 14(8):633-40. PubMed ID: 3326689
[TBL] [Abstract][Full Text] [Related]
11. Effects of the alpha-glucosidase inhibitor 1 desoxynojirimycin (Bay m 1099) on postprandial blood glucose, serum insulin and C-peptide levels in type II diabetic patients.
Schnack C; Röggla G; Luger A; Schernthaner G
Eur J Clin Pharmacol; 1986; 30(4):417-9. PubMed ID: 3527720
[TBL] [Abstract][Full Text] [Related]
12. alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus.
Dimitriadis GD; Tessari P; Go VL; Gerich JE
Metabolism; 1985 Mar; 34(3):261-5. PubMed ID: 3883097
[TBL] [Abstract][Full Text] [Related]
13. The effect of new alpha-glucosidase inhibitors (BAY m 1099 and BAY o 1248) on meal-stimulated increases in glucose and insulin levels in man.
Hillebrand I; Boehme K; Graefe KH; Wehling K
Klin Wochenschr; 1986 Apr; 64(8):393-6. PubMed ID: 3517475
[TBL] [Abstract][Full Text] [Related]
14. Miglitol may have a blood glucose lowering effect unrelated to inhibition of alpha-glucosidase.
Joubert PH; Foukaridis GN; Bopape ML
Eur J Clin Pharmacol; 1987; 31(6):723-4. PubMed ID: 3549325
[TBL] [Abstract][Full Text] [Related]
15. Effects of prolonged administration of two new alpha-glucosidase inhibitors on blood glucose control, insulin requirements and breath hydrogen excretion in patients with insulin-dependent diabetes mellitus.
Dimitriadis G; Hatziagelaki E; Ladas S; Linos A; Hillebrand I; Raptis S
Eur J Clin Invest; 1988 Feb; 18(1):33-8. PubMed ID: 3130257
[TBL] [Abstract][Full Text] [Related]
16. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
Jovanovic L; Giammattei J; Acquistapace M; Bornstein K; Sommermann E; Pettitt DJ
Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
[TBL] [Abstract][Full Text] [Related]
17. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
Mitrakou A; Tountas N; Raptis AE; Bauer RJ; Schulz H; Raptis SA
Diabet Med; 1998 Aug; 15(8):657-60. PubMed ID: 9702468
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of glycemic and hormonal responses after repetitive sucrose and starch loads by different doses of the alpha-glucosidase inhibitor miglitol (BAY m 1099) in man.
Lembcke B; Fölsch UR; Gatzemeier W; Ebert R; Siegel E; Creutzfeldt W
Pharmacology; 1991; 43(6):318-28. PubMed ID: 1784628
[TBL] [Abstract][Full Text] [Related]
19. Metabolic consequences of the alpha-glucosidase inhibitor BAY-M-1099 given to nondiabetic and diabetic rats fed a high-carbohydrate diet.
Madar Z
Am J Clin Nutr; 1989 Jan; 49(1):106-11. PubMed ID: 2643291
[TBL] [Abstract][Full Text] [Related]
20. Effects of BAYm 1099, new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo.
Samad AH; Ty Willing TS; Alberti KG; Taylor R
Diabetes Care; 1988 Apr; 11(4):337-44. PubMed ID: 3042310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
